Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,193,229

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,193,229
Title:Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
Abstract: Disclosed are methods of treating a hyperproliferative disorder or a disease related to vasculogenesis or angiogenesis in a mammal, comprising administering to said mammal an effective amount of a compound of the formula ##STR00001## or a pharmaceutically accepted salt thereof, wherein A, R.sup.1, R.sup.2, R.sup.7, R.sup.8, and R.sup.9 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals.
Inventor(s): Wallace; Eli M. (Boulder, CO), Lyssikatos; Joseph P. (Piedmont, CA), Marlow; Allison L. (Boulder, CO), Hurley; T. Brian (Boulder, CO)
Assignee: Array Biopharma Inc. (Boulder, CO)
Application Number:12/824,521
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,193,229

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes   Request a Trial   Request a Trial METHOD OF TREATING MELANOMA   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,193,229

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 038971   Request a Trial
Argentina 045738   Request a Trial
Argentina 090143   Request a Trial
Argentina 090144   Request a Trial
Austria 449605   Request a Trial
Australia 2003218157   Request a Trial
Australia 2004270166   Request a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.